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Introduction

Results

a.

SO release from leukocytes via NADPH oxidase activation contributes to
oxidative stress under various diseases, such as ischemia/reperfusion (I/R) injury
and vascular complications in diabetes. NADPH oxidase has seven isoforms with
NOX2 being the predominant isoform of NADPH oxidase in polymorphonuclear
b.
leukocytes (PMNs). Activation of NOX2 requires the assembly of cytosolic
subunits (p47phox, p40phox, p67phox, Rac) to membrane subunits (gp91 phox
and p22phox) (1). NADPH oxidase is activated during I/R injury via cytokine
c.
receptor stimulation or chemotactic factor (N-formyl-L-methionyl-L-leucyl-Lphenylalanine (fMLP, MW= 438 g/mol) and utilizes molecular oxygen to produce
SO (2) (fig1). Gp91ds-tat is a peptide which selectivity inhibits NADPH oxidase
assembly by blocking p47phox interaction with gp91phox. It is well known that
adding myristic acid or tat carrier peptide to native peptides will facilitate cell
d.
membrane permeability required for targeting intracellular substrates. The addition
of a glycine-glycine (GG) spacer between the tat and cargo portion of the peptide
is reported to facilitate better delivery of the cargo sequence (i.e., CSTRIRRQL)
Figure 3. a- gp91ds-tat sequence (MW= 2452 g/mol). b- native gp91ds (MW=1131 g/mol). c-gg
(3,4). We have previously shown that myristic acid conjugated caveolin-1 and
spacer (MW=2566 g/mol) d- myristoylated (Myr-peg linker) (MW=1486 g/mol). Adapted from
Rey et al. (3)
protein kinase C (PKC) beta II and zeta peptide inhibitors significantly attenuated
fMLP-induced SO release compared to their native counterparts (5). However, it is
not known if differences exist in the effectiveness of myristic acid versus tat
conjugated gp91 ds-tat peptides compared to their native counterparts or untreated
We
hypothesized
that
myr-gp91ds
(2-10
μM)
would
dose-dependently
attenuate
controls.
fMLP induced PMN SO release at lower concentrations compared to tat conjugated
or tat conjugated gg spacer-gp91ds peptides. Moreover, we also predict that both
myristic acid and tat conjugated gg spacer gp91ds peptides would significantly
attenuate fMLP-induced leukocyte SO release compared to native or untreated
controls without affecting cell viability.

Figure 4. fMLP (1μM)-induced peak response SO release in PMNs. Myr-peg gp91 (5 & 10 μM) significantly
attenuated untreated (*p<0.01) and native gp91 (# p<0.05) induced SO release by 56-57 ± 8% and 52-54 ± 9 %
respectively. Myr-peg gp91 (2 µM), gp91dstat (80 µM), and gg spacer (80 µM) significantly inhibited untreated by
36 ± 11 % compared to untreated controls (*p<.05) and was not different from native gp91. Concentrations of tat
conjugated peptides ≤40 µM did not exert significant inhibition of PMN SO release. (data not shown)

Hypothesis

Figure 5. The time course response of fMLP (1μM)-induced SO release. Myr-peg gp91 (5 & 10 μM) significantly
inhibited untreated (**p<0.01, *p<0.05) and native gp91 (# p<0.05) by 44-56% and 46-52% respectively from 30120 sec. Myr-peg gp91 (2 µM), gp91dstat (80 µM), and gg spacer (80 µM) significantly untreated (*p<0.05) by 3336% from 30-120 sec and was only different from native gp91 at 30 sec (#p<0.05).

Methods
Isolation of PMNs
Male Sprague-Dawley rats (350–400 g, Charles River), used as PMN donors, were
anesthetized with 2.5 % isoflurane and given a 16 ml intraperitoneal injection of
0.5% glycogen (Sigma Chemical) dissolved in PBS. Rats were reanesthetized with
isoflurane 16–18 h later, and the PMNs were harvested by peritoneal lavage in 30 ml
of 0.9% NaCl, as previously described (2,5). The peritoneal lavage fluid was
centrifuged at 200 g for 10 min at 4°C. The PMNs were then washed in 20 ml PBS
and centrifuged at 200 g for 10 min at 4°C. Thereafter, the PMNs were
Figure 1. Schematic representation of PKC activation generating SO release in PMN. PMN
resuspended in 2.5 ml PBS and density was calculated. The PMNs preparation were
chemotactic G-protein receptors are activated by fMLP. The G-protein subunits q and βγ
disassociate after stimulation and activate phospholipase C beta (PLCβ) and phosphatidyl inositol- >90% pure and >95% viable according to microscopic analysis and exclusion of
3-kinase gamma (PI-3kinγ) to produce inositol 1,4,5 trisphosphate (Ins(1,4,5)P2) plus DAG and
0.3% trypan blue, respectively. Cell viability among all study groups was
PtdIns(3,4,5)P2 respectively from phospholipids phosphatidylinositol 4,5 bisphosphate
determined by 0.3% trypan blue exclusion.
(PtdIns(4,5)P2). Ins(1,4,5)P2 stimulates Ca2+ release from the endoplasmic reticulum (ER).
Measurement of SO Release From Rat PMNs
2+
Ca /DAG and PtdIns(3,4,5)P2 directly activate PKC. Activated PKC phosphorylates NADPH
The SO release from PMNs was measured spectrophotometrically (model 260
oxidase to release SO anion. Adapted from Young et al. (2)
Gilford, Nova Biotech; El Cajon, CA) by the reduction of ferricytochrome c (2,5).
The PMNs (5 x106) were resuspended in 450 μl PBS and incubated with
ferricytochrome c (100 µM, Sigma Chemical) in a total volume of 900 μl PBS in the
presence or absence of myristric acid conjugated (2 to 10 μM), tat conjugated (80
µM) or native gp91ds (80 µM) for 15 min at 37°C in spectrophotometric cells. The
PMNs were stimulated with 1 μM fMLP (Calbiochem) in a final reaction volume of
1.0 ml. Absorbance at 550 nm was measured every 30 sec for up to 120 sec for
fMLP and the change in absorbance (SO release) from PMNs was determined
relative to time 0.
Cell Viability
Cell viability was determined by combining 0.5 ml of the samples from
spectrophotometric analysis using trypan blue exclusion (0.3%). Then, 20 μl of the
combined sample was placed on to a hemocytometer, and 100-150 cells were
gp91ds-tat
subsequently counted using microscopic analysis.
Statistical Analysis
Figure 2. Schematic showing the inactive and active forms of NADPH oxidase. Green-lines All data in the text and figures are presented as means ± S.E.M. The data were
denote areas of inhibition performed by gp91ds-tat. Adapted from Wilkinson et al. (1)
analyzed by analysis of variance using post hoc analysis with the Fisher’s test.
Probability values of <0.05 are considered to be statistically significant.

Figure 6. The effects of native, tat, and myristoylated conjugated gp91 on cell viability in fMLP (1 μM)-induced SO
release in PMNs. Cell viability ranged between 90-93% ± 1 and was not different amongst study groups indicating
that the reduction in SO release were not related to cell death.

Conclusions
Unconjugated native sequence did not inhibit the fMLP induced SO response at
the highest dose tested (80 µM). Myr-peg gp91ds NADPH oxidase peptide
inhibitor significantly attenuated leukocyte SO release dose dependently
compared to untreated or native sequence (myr-peg-gp91ds; 5-10 µM). The tat
conjugated gp91ds inhibitors (both 80 µM) significantly attenuated fMLPinduced leukocyte SO release, but to a lesser extent than the myr-peg linked
inhibitor and were not different from native gp91ds. These results suggest that
myr-peg-gp91ds is more cell permeable and therefore can inhibit fMLP-induced
SO release from leukocytes at lower doses compared to tat gp91ds.
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